Research programme: kainate receptor antagonists - Biotie Therapies

Drug Profile

Research programme: kainate receptor antagonists - Biotie Therapies

Alternative Names: E099-255011; GluR5 receptor antagonists; GluR6 receptor antagonists

Latest Information Update: 02 Mar 2017

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator elbion GmbH
  • Developer biocrea GmbH
  • Class Indoles; Small molecules
  • Mechanism of Action Kainic acid receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Neurodegenerative disorders

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for research development in Neurodegenerative-disorders in Germany
  • 14 Nov 2008 elbion GmbH has been acquired by BioTie Therapies
  • 04 Sep 2008 Early research in Neurodegenerative disorders in Germany (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top